EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Spinal leptomeningeal disease in patients with solid tumors: A single-center study on clinical presentation, diagnosis, treatment, and outcomes

Zoe Shaked, Chiara Eitner, Claudius Jelgersma, Anton Früh, Ran Xu, Helena Radbruch, Jawed Nawabi, Felix Ehret, Güliz Acker, Daniel Zips, Lars Wessels, Ulrich Keilholz und 4 weitere

Brain and Spine · 2026 · 6 · 106660

DOI: 10.1016/j.bas.2026.106660 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain and Spine, 2026. Verfasst von Zoe Shaked und 15 weiteren Autor:innen. Beteiligte Einrichtung: Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurosurgery, Be…. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charité – Universitätsmedizin Berlin, Berlin Institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Despite affecting 5-15% of metastatic cancer patients, leptomeningeal disease (LMD), and spinal LMD (sLMD) in particular, remain largely understudied. Research question: This study evaluates the clinical presentation, diagnosis, treatment, and outcomes of sLMD. Material and methods: We retrospectively analyzed sLMD patients treated at a tertiary center (2011-2024) who underwent cranial and spinal imaging within 30 days of LMD diagnosis. Survival analysis was performed using Kaplan-Meier curves, with a multivariable Cox regression model being employed to identify independent prognostic factors using a stepwise backwards approach.

Results

Fifty-two patients (median age: 57.9 years, 63.5% female) were included. Breast cancer (30.8%) and NSCLC (25.0%) were the most common primary malignancies. Median time from primary disease diagnosis to LMD diagnosis was 30.2 months [95% CI: 18.9-42.6]. LMD was diagnosed in 51.9% of cases through imaging and in 48.1% through imaging and CSF cytology. At diagnosis, 92.3% had concurrent cranial and spinal LMD, 67.3% brain metastases, 50.0% vertebral metastases, and 19.2% intraspinal metastases. The most common symptoms were clinical decline (80.8%) and headaches (59.6%). Spine-related symptoms included radiculopathy (26.9%) and paraplegia (23.1%). Median overall survival was 2.7 months [95% CI: 2.0-4.1]. Independent prognostic factors for improved survival included systemic therapy following LMD diagnosis (HR = 0.40, p < 0.01), absence of cranial nerve deficits (HR = 0.45, p < 0.05) and absence of gait imbalance (HR = 0.50, p < 0.05) at LMD diagnosis. Discussion and conclusion: By highlighting the clinical challenges, heterogenous treatment regimens and poor prognosis associated with sLMD, this study serves as a foundation for further research aimed at improving management strategies and outcomes for this patient cohort.

Schlagwörter

Stichwörter der Autor:innen

Intraspinal metastasisLeptomeningeal diseaseSpinal leptomeningeal diseaseSurvivalVertebral metastasis

Autor:innen und Institutionen

  • Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurosurgery, Berlin, Germany.
  • German Center for Cardiovascular Research (DZKK), Berlin, Germany.
  • Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neuropathology, Berlin, Germany.
  • Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neuroradiology, Berlin, Germany.
  • Berlin Institute of Health at Charité, Universitätsmedizin Berlin, Berlin Institute of Health (BIH) Charité, Charitéplatz 1, Berlin, 10117, Germany.
  • Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Radiation Oncology, Berlin, Germany.

Förderung

  • Charité – Universitätsmedizin Berlin
  • Berlin Institute of Health

Zitieren

APA

Shaked, Z., Eitner, C., Jelgersma, C., Früh, A., Xu, R., Radbruch, H., Nawabi, J., Ehret, F., Acker, G., Zips, D., Wessels, L., Keilholz, U., Onken, J., Misch, M., Vajkoczy, P., & Wasilewski, D. (2026). Spinal leptomeningeal disease in patients with solid tumors: A single-center study on clinical presentation, diagnosis, treatment, and outcomes. Brain and Spine, 6, 106660. https://doi.org/10.1016/j.bas.2026.106660

Vancouver

Shaked Z, Eitner C, Jelgersma C, Früh A, Xu R, Radbruch H, et al. Spinal leptomeningeal disease in patients with solid tumors: A single-center study on clinical presentation, diagnosis, treatment, and outcomes. Brain and Spine. 2026;6:106660. doi:10.1016/j.bas.2026.106660

BibTeX
@article{Shaked2026,
  author = {Shaked, Zoe and Eitner, Chiara and Jelgersma, Claudius and Früh, Anton and Xu, Ran and Radbruch, Helena and Nawabi, Jawed and Ehret, Felix and Acker, Güliz and Zips, Daniel and Wessels, Lars and Keilholz, Ulrich and Onken, Julia and Misch, Martin and Vajkoczy, Peter and Wasilewski, David},
  title = {Spinal leptomeningeal disease in patients with solid tumors: A single-center study on clinical presentation, diagnosis, treatment, and outcomes},
  journal = {Brain and Spine},
  year = {2026},
  volume = {6},
  pages = {106660},
  doi = {10.1016/j.bas.2026.106660}
}
Kostenlos starten →